6-氨基咪唑并[1,2-a]吡啶-2-甲酸乙酯 | 158980-21-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 酯类氨基酸
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 6-氨基咪唑并[1,2-a]吡啶-2-甲酸乙酯
• 中文别名: 6-氨基咪唑并[1,2-A]吡啶-2-羧酸乙酯
• 英文名称: ethyl 6-aminoimidazo[1,2-a]pyridine-2-carboxylate
• CAS: 158980-21-3
• 化学式: C₁₀H₁₁N₃O₂
• 分子量: 205.216
• InChiKey: PKWHXLCNUIXDIK-UHFFFAOYSA-N

物化性质

• 密度：
  1.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R43
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  2-8℃

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Aminoimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H317: May cause an allergic skin reaction
P280: Wear protective gloves/protective clothing/eye protection/face protection

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Aminoimidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester
CAS number: 158980-21-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H11N3O2
Molecular weight: 205.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氨基咪唑并[1,2-a]吡啶-2-甲酸乙酯 在 palladium on activated charcoal 、 水 、 甲酸铵 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 N,N-二甲基乙酰胺 为溶剂， 反应 24.17h， 生成 (S)-N-(2-(1-(chloromethyl)-5-hydroxy-9-methyl-2,3-dihydro-1H-benzo[e]indole-3-carbonyl)-imidazo[1,2-a]pyridin-6-yl)-4-(methoxymethoxy)benzamide
  参考文献：
  名称：

  [EN] IMPROVED PROCESS FOR MAKING DUOCARMYCIN PRODRUGS
  [FR] PROCÉDÉ AMÉLIORÉ DE PRODUCTION DE PROMÉDICAMENTS À BASE DE DUOCARMYCINE

  摘要：

  本发明涉及一种过程，包括将式（I）的化合物通过与有机锂试剂发生反应转化为式（II）的化合物，该化合物可以进一步转化为由DNA烷基化部分和DNA结合部分组成的杜卡霉素类似物，更进一步转化为相应的抗体药物结合物。

  公开号：

  WO2015185142A1
• 作为产物：
  描述：

  6-硝基咪唑[1,2-Alpha]吡啶-2-羧酸乙酯 在 钯 乙醇 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 6-氨基咪唑并[1,2-a]吡啶-2-甲酸乙酯
  参考文献：
  名称：

  SUBSTITUTED OXOPYRIDINE DERIVATIVES

  摘要：

  本发明涉及取代的氧代吡啶衍生物及其制备方法，以及它们用于制备治疗和/或预防疾病的药物，特别是心血管疾病，优选的是血栓或栓塞性疾病，水肿和眼科疾病。

  公开号：

  US20160272637A1

文献信息

• ANDROGEN RECEPTOR MODULATING CARBOXAMIDES
  申请人：Törmakängas Olli

  公开号：US20140094474A1

  公开（公告）日：2014-04-03

  Compounds of formula (I) or (II) wherein R x , R z , R 9 , R 10 , R 14 , R 14 ′, R 15 , R 15 ′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

  式(I)或(II)的化合物 其中R x ，R z ，R 9 ，R 10 ，R 14 ，R 14 ′，R 15 ，R 15 ′，A和B如权利要求中所定义，并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他依赖于AR的疾病和病症中，需要AR拮抗作用时可用作药物。
• [EN] ANDROGEN RECEPTOR MODULATING CARBOXAMIDES<br/>[FR] CARBOXAMIDES MODULANT LES RÉCEPTEURS D'ANDROGÈNES
  申请人：ORION CORP

  公开号：WO2012143599A1

  公开（公告）日：2012-10-26

  Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

  公式（I）中的化合物，其中Rx、Rz、R9、R10、R14、R14'、R15、R15'、A和B的定义如索赔中所述，并且其药学上可接受的盐和酯已被披露。这些化合物具有作为组织选择性雄激素受体调节剂（SARM）的效用，并且在治疗前列腺癌和其他依赖于雄激素受体的疾病和病症中特别有用，其中需要AR拮抗作用。
• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019102494A1

  公开（公告）日：2019-05-31

  The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

  公式I、公式Ia和公式Ib的化合物以及它们的类似物、互变异构体、对映异构体、多态性、水合物、溶剂化物、药物可接受的盐、药物组合物、代谢物和前药在本文件中进行了描述。这些化合物抑制PRMT5，并可作为治疗或改善与细胞生长相关的疾病，如恶性肿瘤、精神分裂症、阿尔茨海默病、帕金森病等的治疗或改善剂。
• [EN] PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY<br/>[FR] PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACÉTAMIDES UTILISÉS COMME INHIBITEURS DE LA VOIE DE L'INFLAMMASOME NLRP3
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021209552A1

  公开（公告）日：2021-10-21

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  这项发明涉及用作NLRP3炎症小体产生抑制剂的新化合物，其中这些化合物由式(I)的化合物定义，并且整数R1、R2和R3在描述中有定义，这些化合物可能作为药物有用，例如用于治疗与NLRP3炎症小体活性相关的疾病或紊乱。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021239885A1

  公开（公告）日：2021-12-02

  The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.

  本发明涉及用于抑制NLRP3炎症体产生的新化合物，其中所述化合物由公式（I）定义，其中整数R1、R2和R3在描述中定义，且所述化合物可用作药物，例如用于治疗与NLRP3炎症体活性相关的一种疾病或失调。